U.S. License Holder:
Novartis Pharms.
Date of License:
June-17-2009
Last Update:
Dec-15-2024
FDA-Approved Indications
ILARIS (canakinumab) is an interleukin-1 beta blocker indicated for the treatment of:
Periodic Fever Syndromes:
Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: Familial Cold Autoinflammatory Syndrome (FCAS); Muckle-Wells Syndrome (MWS);
Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients;
Hyperimmunoglobulin D Syndrome (HIDS) / Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients; and
Familial Mediterranean Fever (FMF) in adult and pediatric patients;
Active Still's Disease, including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older;
Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.